Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma.

Abstract

The wide prevalence of BRAF mutations in diagnosed melanomas drove the clinical advancement of BRAF inhibitors in combination with immune checkpoint blockade for treatment of advanced disease. However, deficits in therapeutic potencies and safety profiles motivate the development of more effective strategies that improve the combination therapy's therapeutic index. Herein, we demonstrate the benefits of a locoregional chemoimmunotherapy delivery system, a novel thermosensitive hydrogel comprised of gelatin and Pluronic® F127 components already widely used in humans in both commercial and clinical products, for the co-delivery of a small molecule BRAF inhibitor with immune checkpoint blockade antibody for the treatment of BRAF-mutated melanoma. In vivo evaluation of administration route and immune checkpoint target effects revealed intratumoral administration of antagonistic programmed cell death protein 1 antibody (aPD-1) lead to potent antitumor therapy in combination with BRAF inhibitor vemurafenib. The thermosensitive F127-g-Gelatin hydrogel that was evaluated in multiple murine models of BRAF-mutated melanoma that facilitated prolonged local drug release within the tumor (>1 week) substantially improved local immunomodulation, tumor control, rates of tumor response, and animal survival. Thermosensitive F127-g-Gelatin hydrogels thus improve upon the clinical benefits of vemurafenib and aPD-1 in a locoregional chemoimmunotherapy approach for the treatment of BRAF-mutated melanoma.

• Authors: Jihoon Kim, Paul A Archer, Margaret P Manspeaker, Alexa R C Avecilla, Brian P Pollack, Susan N Thomas
• Journal: Journal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 357 Pg. 655-668 (05 2023) ISSN: 1873-4995 [Electronic] Netherlands
• PMID: 37080489 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2023. Published by Elsevier B.V.

Chemical References

• Vemurafenib
• Proto-Oncogene Proteins B-raf
• Immune Checkpoint Inhibitors
• Hydrogels
• Gelatin
• UCON 50-HB-5100
• Delayed-Action Preparations
• Protein Kinase Inhibitors
• BRAF protein, human

Topics

• Humans
• Animals
• Mice
• Vemurafenib (therapeutic use)
• Proto-Oncogene Proteins B-raf (genetics)
• Immune Checkpoint Inhibitors (therapeutic use)
• Hydrogels (therapeutic use)
• Gelatin
• Delayed-Action Preparations (therapeutic use)
• Melanoma (drug therapy, genetics)
• Protein Kinase Inhibitors
• Mutation